Molecular imaging of prostate cancer is in a dynamic phase of development. Currently approved techniques are limited and researchers have been working on novel agents to improve accuracy in targeting and detecting prostate tumors.
In addition, the complexity of various prostate cancer states also contributes to the challenges in evaluating suitable radiotracer candidates. We have highlighted nuclear medicine tracers that focus on mechanisms involved in bone metastasis, prostate cancer cell membrane synthesis, amino acid analogs, androgen analogs, and the prostate specific membrane antigen. Encouraging results with many of these innovative radiotracer compounds will not only advance diagnostic capabilities for prostate cancer but open opportunities for theranostic applications to treat this worldwide malignancy.
Current urology reports. 2016 Mar [Epub]
Liza Lindenberg, Peter Choyke, William Dahut
Center for Cancer Research, National Cancer Institute, BG 10-CRC RM 3-2571 MSC 1206, 10 Center Dr, Bethesda, MD, 20892-1206, USA. Center for Cancer Research, National Cancer Institute, BG 10-CRC RM 3-2571 MSC 1206, 10 Center Dr, Bethesda, MD, 20892-1206, USA. Center for Cancer Research, National Cancer Institute, BG 10-CRC RM 3-2571 MSC 1206, 10 Center Dr, Bethesda, MD, 20892-1206, USA.